Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q2 2018 · 10-Q
Revenue$379.00K$379.00K+24.3% vs Q2 2017 Net Income-$18.39M-$18.39MN/M vs Q2 2017 EPS Diluted$0.74$0.74N/M vs Q2 2017 Operating Income-$18,951,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,149,000— Margins · derivedOperating margin-5000.3%−461.9 pt vs Q2 2017
Net margin-4851.7%−379.9 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end